🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the effort against superbug strains of the bacteria, according to scientists.

A Global Health Concern

Cases of gonorrhoea are increasing around the world, with estimates suggesting more than 82 million infections annually. Notably increased rates are seen in Africa and nations within the WHO's designated area, which encompasses Mongolia and China to New Zealand. In England, cases have hit a all-time high, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an important and timely development in the face of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce treatment choices currently available.”

Public health authorities are particularly alarmed about the surge in treatment-resistant strains. The global health body has designated it as a "priority pathogen". Recent surveillance revealed that the effectiveness of key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

A Pair of Novel Therapies Secure Authorization

One new antibiotic, also known as a brand name, was approved by the American regulatory agency in recent days for use against gonorrhoea. This STI can lead to serious health problems, including infertility. Researchers hope that focused deployment of this new drug will help slow the spread of drug resistance.

Another new antibiotic, created by the drugmaker GlaxoSmithKline, also received approval in the same week. This treatment, which is employed against urinary tract infections, was demonstrated in studies to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment was the result of a innovative non-profit model for drug creation. The charitable organization GARDP partnered with the pharmaceutical company its industry partner to develop it.

“This milestone marks a major breakthrough in the management of multidrug-resistant gonorrhoea, which until now has been evolving faster than antibiotic development.”

Clinical Trial Data and Global Access

As per findings published in a prominent scientific publication, the new drug cured more than 90% of cases of the STI. This establishes an similar efficacy with the existing first-line therapy, which uses two antibiotics. The trial included nearly 1,000 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, GARDP has the authority to license and sell the drug in numerous regions with limited resources.

Clinicians directly involved have expressed optimism. Access to a single-dose, oral treatment like this is hailed as a "critical tool" for public health efforts. This is deemed crucial to reduce the burden of the infection for individuals and to stop the proliferation of highly drug-resistant gonorrhoea around the world.